The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRBU | +44.16% | N/A | N/A | -83% |
| S&P | +15.06% | +95.03% | +14.29% | +53% |
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
These CRISPR stocks could be big winners for patient investors.
These exchange-traded funds track companies in this biotech space.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.67M | -23.0% |
| Gross Profit | $1.50M | -42.5% |
| Gross Margin | 56.24% | -19.0% |
| Market Cap | $117.19M | -20.9% |
| Market Cap / Employee | $0.80M | 0.0% |
| Employees | 147 | -7.0% |
| Net Income | -$54.10M | -43.5% |
| EBITDA | -$34.26M | 19.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.20M | -33.4% |
| Accounts Receivable | $0.82M | -30.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $23.56M | -7.7% |
| Short Term Debt | $2.29M | 27.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.32% | -21.2% |
| Return On Invested Capital | -61.90% | -1.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$28.68M | 18.3% |
| Operating Free Cash Flow | -$28.26M | 14.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.63 | 0.51 | 0.33 | 0.54 | 25.03% |
| Price to Sales | 15.45 | 14.50 | 8.53 | 12.85 | 187.22% |
| Price to Tangible Book Value | 0.63 | 0.51 | 0.33 | 0.54 | 25.03% |
| Enterprise Value to EBITDA | 0.65 | 1.01 | 2.34 | 1.19 | -40.94% |
| Return on Equity | -43.6% | -48.0% | -52.8% | -68.9% | 61.92% |
| Total Debt | $26.66M | $26.51M | $26.22M | $25.85M | -5.41% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
